Clinical Trial

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Shelf-stable donor milk pioneer Leche and testing firm Tiny Health launch a study to see if a little breast milk can make a big difference for formula-fed babies.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Precision IO Group is showcasing its AI-guided Epione robot and a vision for remote cancer surgery, aiming to erase geographic barriers to expert care.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

SpotitEarly's novel platform combines trained dogs and machine learning for non-invasive cancer detection. A new partnership aims to bring it to market by 2027.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.